Hubei Biocause Heilen Pharmaceutical Co., Ltd. (SHE:301211)

Market Cap	5.30B +6.8%
Revenue (ttm)	466.05M +6.2%
Net Income	46.50M +11.8%
EPS	0.11 +17.4%
Shares Out	417.60M
PE Ratio	114.66
Forward PE	n/a
Dividend	0.06 (0.47%)
Ex-Dividend Date	Jun 12, 2026

Volume	12,320,208
Open	12.54
Previous Close	12.44
Day's Range	12.38 - 12.83
52-Week Range	9.01 - 16.95
Beta	0.54
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 27, 2026

About SHE:301211

Hubei Biocause Heilen Pharmaceutical Co., Ltd. engages in the pharmaceutical, chemical, and new energy fuel businesses in China and internationally. It is involved in the research and development, production, and sales of chemical raw materials and preparations; and provision of contract research and development, and production services. The company also provides raw material products, including non-steroidal anti-inflammatory raw materials ibuprofen and dexibuprofen, cardiovascular raw materials torsemide and milrinone, anti-tumor raw material...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1995
• Employees: 952
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 301211

Financial Performance

In 2025, SHE:301211's revenue was 453.31 million, an increase of 1.67% compared to the previous year's 445.86 million. Earnings were 34.91 million, a decrease of -61.87%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 2, 2026

Data Sources Report a data error